Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Dilutive issuance
confidence 75%
filed 2026-08-03
The filing discloses a reverse stock split (1-for-8) approved by shareholders and the Board, effective August 6, 2026. More significantly, it reveals concurrent dilutive issuances: a private placement of 10,000,000 Class A shares closed on August 3, 2026, and 2,400,000 Class A shares issued under the 2026 Share Incentive Plan (Form S-8 filed same date), plus up to 2,000,000 additional shares upon warrant exercise. These equity issuances, particularly the private placement and warrant dilution, are material capital events that would affect investor assessment of ownership and voting power.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-03
EX-99.1
The press release discloses that Nuvini received a Nasdaq staff determination letter on July 28, 2026 stating that the Company failed to regain compliance with the minimum Market Value of Listed Securities requirement ($35 million) by the July 27 deadline. The letter indicates trading would be suspended and a Form 25-NSE would be filed absent a hearing request. Although the Company has requested a hearing that stays suspension, the disclosure explicitly addresses delisting risk and the Company's plan to regain compliance under an alternative listing standard, making this a material delisting-risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Exec departure
confidence 72%
filed 2026-08-03
Item 5.02
The filing discloses the resignation of Mr. Sheng-Kai (Scott) Hsu, the Chief Financial Officer, effective August 1, 2026, due to personal reasons with no disagreement cited. While the disclosure also includes the appointment of Mr. Tong Wu as Interim CFO, the principal event centers on the departure of the CFO—a named executive officer whose resignation creates a material vacancy in a critical financial role. The CFO departure is the triggering event; the interim appointment is the remedial response.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-08-03
Mr. Tang Chak Ming resigned from his positions as Chief Financial Officer and director of Everbright Digital Holding Limited, effective immediately on July 31, 2026. The departure of a CFO and board member is a material executive departure that would affect a reasonable investor's assessment of the company's leadership and financial oversight.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-03
The 6-K discloses the appointment of Ms. Qian Yi Amanda Chew as Chief Product Officer (CPO) by the Board of Directors, effective August 17, 2026. This is a named executive appointment to a C-suite officer position, representing a material change in leadership that would affect a reasonable investor's assessment of the company's management structure and strategic direction.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-03
U Power Limited entered into subscription agreements on August 3, 2026, to issue 9,756,100 Class A ordinary shares at $1.64 per share for aggregate proceeds of $16.0 million to four non-U.S. purchasers under Regulation S. This is an unregistered private placement of equity securities that dilutes existing shareholders and raises material capital for the company's hydrogen energy and data center initiatives in Thailand.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-08-03
Item 1.01
Churchill Capital Corp XIII consummated its IPO on August 3, 2026, raising $414 million in gross proceeds through the issuance of 41.4 million units. The company entered into multiple material definitive agreements (underwriting agreement, warrant agreements, trust agreement, registration rights agreement, and private placement agreement) in connection with the offering.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-03
Item 3.02
Churchill Capital Corp XIII completed a private placement of 350,000 units to the Sponsor at $10.00 per unit ($3.5 million gross proceeds) pursuant to Section 4(a)(2) exemption from registration, concurrent with the IPO closing.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-03
Item 5.02
William Sherman was appointed to the Board of Directors effective July 31, 2026, and simultaneously appointed as interim chair of the Audit Committee and chair of the Compensation Committee.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-08-03
Ms. Zoe Yong Goon Wey resigned from her position as independent director effective August 1, 2026, as disclosed in the Board's resignation letter received July 30, 2026. The departure of a board member, particularly an independent director, is a material governance event that would affect a reasonable investor's assessment of the company's board composition and independence.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-03
The filing discloses results of HeartBeam's annual meeting of stockholders held on July 31, 2026, under Item 5.07. It reports voting outcomes for three matters: election of seven directors (all approved), ratification of CBIZ CPAs P.C. as independent auditor (approved), and a proposal to amend the 2022 Equity Incentive Plan to increase authorized shares by 3,000,000 (not approved). This is a standard shareholder vote results disclosure materially affecting investor understanding of governance and capital structure decisions.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-08-03
EX-99.1
The press release announces completion of PicPay's acquisition of Kovr Participações S.A. and its subsidiaries, a digital insurance technology company. The transaction involved acquisition of 100% of Kovr shares and 53% of Estrutural Corretora with a call option on remaining quotas, following regulatory approvals from CADE, SUSEP, and Bacen. This is a material acquisition completion that would affect investor assessment of the registrant's strategic direction and financial position.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-03
EX-99.1
The press release announces a private placement of 1,750,000 ADSs at $2.00 per ADS with accompanying Series E and Series F warrants, generating $3.5 million upfront with up to $7 million in potential additional proceeds. This is an unregistered equity issuance under Section 4(a)(2) and Regulation D, which is dilutive to existing shareholders and material to investor assessment of capital structure and ownership.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-03
The 8-K discloses Gulfport Energy's second quarter 2026 financial and operating results under Item 2.02, with a press release reporting net income of $87.1 million, adjusted EBITDA of $179.1 million, production of 962.8 MMcfe per day, and updated capital expenditure guidance. This is a standard quarterly earnings disclosure material to investors assessing the company's financial performance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-03
NewcelX disclosed entry into definitive securities purchase agreements on July 31, 2026, for a private placement of 347,134 common shares and common warrants at $4.033 per share, expected to raise $1.4 million in gross proceeds with potential additional $1.5 million from warrant exercise. The securities are being offered under Section 4(a)(2) and Regulation D Rule 506(b) exemptions to accredited investors, and the company committed to file a registration statement for resale within 45 days. This is a classic dilutive equity issuance material to investors assessing ownership and capital structure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-03
EX-99.1
Wetour Robotics announced it is pursuing a cooperation agreement with a warehouse robotics company to support implementation of its Orchestra commercial project, with management estimating approximately US$5.0 million in project-level gross profit upon full rollout. This is a material operational/strategic partnership announcement that would affect investor assessment of the company's commercial execution capability and revenue potential, though the agreement remains subject to negotiation and no definitive documentation has been executed as of the release date.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-03
EX-99.1
The press release announces the appointment of Mr. Martin Ngai Lam Cheung as an independent director of Pinnacle Food Group Limited, effective August 1, 2026. The disclosure details his extensive qualifications, including prior board and audit committee experience at multiple public companies, CFO tenure at China Zenix Auto International Limited, and professional certifications. The Board has determined he meets independence requirements under Nasdaq Listing Rule 5605(a)(2) and qualifies as an "audit committee financial expert." This is a clear executive/director appointment that would be material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-03
Item 1.01
Newbridge Acquisition Limited entered into a Business Combination Agreement with Startech Group Inc., whereby a merger subsidiary will merge with Startech, resulting in Startech becoming a wholly owned subsidiary of the domesticated parent company. Startech stockholders will receive 100,000,000 common shares valued at approximately $1 billion in aggregate consideration. The transaction has been unanimously approved by both boards and is subject to shareholder approval and regulatory conditions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-03
Item 5.07
This 8-K Item 5.07 discloses the results of Jasper Therapeutics' 2026 Annual Meeting of Stockholders held on July 31, 2026, including voting outcomes for four proposals: election of two Class II directors (Judith Shizuru and Tom Wiggans), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (votes for, against, abstentions, and broker non-votes) for each proposal, which is the standard disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-03
LogicMark, Inc. entered into an Agreement and Plan of Merger dated July 31, 2026, whereby Langham Merger Sub will merge with and into the Company, with the Company continuing as a wholly-owned subsidiary of Parent. The merger price is $1.31 per share of common stock. This is a material acquisition/change of control transaction requiring shareholder approval and resulting in the Company ceasing to be a public reporting company, clearly falling under Item 1.01 (Entry into a Material Definitive Agreement) and the ma_activity event type.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-08-03
Item 8.01
The filing discloses a postponement of a previously announced distribution of ordinary shares of BioKey (Cayman), Inc. to shareholders of ABVC BioPharma. Although the distribution is delayed rather than completed, the event concerns a material capital distribution to shareholders with a specified distribution ratio (0.169464 shares per share held), making it a dividend_distribution event. The postponement itself is material to investors as it affects the timing and mechanics of a shareholder distribution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-03
Item 1.01
Alzamend Neuro entered into a Securities Purchase Agreement with Ault Lending to sell up to $25 million in Series D convertible preferred stock ($7.5 million closed initially) under Section 4(a)(2) exemption. The preferred shares are convertible into common stock at a conversion price subject to downward adjustment with anti-dilution provisions, resulting in substantial common stock dilution upon conversion, particularly given the 80% lookback conversion pricing mechanism.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-03
Item 3.01
Alzamend Neuro disclosed non-compliance with Nasdaq Listing Rule 5605(b)(1) requiring a majority independent board, triggered by the death of an independent director. Nasdaq has provided a cure period through July 20, 2027 (or earlier if the annual meeting occurs before January 18, 2027), with material uncertainty about whether compliance will be achieved within the cure period.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
Jazz Pharmaceuticals issued a press release on August 3, 2026 announcing second quarter 2026 financial results, including total revenues of $1.2 billion (+16% YoY), GAAP EPS of $2.78, and raised full-year 2026 revenue guidance to $4.60-$4.75 billion. The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly discloses quarterly financial results, which is the hallmark of an earnings release.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-08-03
EX-99.1
This is an announcement of a shareholder call to discuss Q2 2026 financial results, with the Company's financial statements to be released on August 13, 2026. While the exhibit itself is a notice of the call rather than the results press release proper, it announces the imminent disclosure of quarterly financial performance and is materially relevant to investors assessing the registrant's operational and financial status.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-03
Item 7.01
The filing discloses a strategic equity investment by the U.S. Department of War of approximately US$35.6 million in Trilogy Metals, with a letter of intent signed in October 2025 remaining in effect. The press release explicitly includes a "U.S. Securities Act Disclaimer" stating the securities "have not been registered under the Securities Act of 1933" and are being offered in a transaction "not involving a public offering," which is characteristic of a private placement or unregistered equity issuance. This represents a material dilutive capital raise that would affect investor assessment of ownership and capitalization.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-03
Petrobras announces a new gas discovery in the Sandia-1 exploratory well in Block GUA-OFF-O offshore Colombia. The disclosure emphasizes the discovery's contribution to reserve replenishment and regional energy security as part of the company's long-term exploration strategy. While not a discrete M&A transaction or operational restructuring, this exploration milestone represents a material operational and strategic development affecting the registrant's reserve base and future production potential.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
InvenTrust Properties Corp. issued a press release on August 3, 2026 announcing its financial and operating results for the quarter ended June 30, 2026, including Net Income, Nareit FFO, Core FFO, Same Property NOI growth, and updated 2026 guidance. This is a standard quarterly earnings release disclosure under Item 2.02, with the full text attached as Exhibit 99.1 and supplemental information as Exhibit 99.2.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-03
Item 2.02
Palantir Technologies issued a press release on August 3, 2026 announcing Q2 2026 financial results with revenue of $1.935 billion (93% YoY growth) and net income of $1.062 billion, while raising full-year 2026 revenue guidance to $8.150–$8.158 billion (82% YoY growth). The disclosure includes detailed financial statements and CEO commentary.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
Duke Energy's Item 2.02 disclosure announces second-quarter 2026 financial results with reported EPS of $1.38 and adjusted EPS of $1.43, compared to $1.25 in Q2 2025. The news release (Exhibit 99.1) provides comprehensive quarterly earnings data, segment performance, guidance reaffirmation, and management commentary. This is a standard quarterly earnings announcement furnished pursuant to Item 2.02.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-03
Item 3.02
GameStop entered into privately negotiated exchange agreements to exchange approximately $1.4 billion in aggregate principal amount of convertible senior notes (2030 and 2032 Notes) for shares of Class A common stock in an unregistered private placement to accredited investors and qualified institutional buyers. The company will receive no cash proceeds, and the transaction materially dilutes existing shareholders' ownership percentages through the issuance of an unspecified number of shares.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
Boise Cascade issued a press release on August 3, 2026, announcing second quarter 2026 financial results, including net income of $57.3 million ($1.63 per share) on sales of $1.8 billion, with detailed segment performance, balance sheet metrics, capital allocation, and forward guidance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-03
Item 8.01
Boise Cascade's subsidiary entered into a material 10-year exclusive distribution agreement with James Hardie, effective July 31, 2026, making Boise Cascade the sole nationwide distributor of James Hardie's exterior building products portfolio, with the distributor required to purchase exclusively from the supplier and transition away from competing product lines.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-03
Item 2.02
Leidos disclosed financial results for the second fiscal quarter ended July 3, 2026, via a press release issued on August 4, 2026. The disclosure includes key metrics: revenues of $4.6 billion (up 7% YoY), net income of $356 million ($2.81 per diluted share), adjusted EBITDA of $631 million, and free cash flow of $761 million. The company also raised full-year 2026 guidance for revenues, non-GAAP diluted EPS, and operating cash flows. This is a standard quarterly earnings release filed under Item 2.02 with the press release furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-08-03
Item 2.02
The Item 2.02 disclosure centers on Supernus's second quarter 2026 financial results, with total revenues of $219.1 million (32% increase YoY) and updated full-year 2026 guidance. The press release (Exhibit 99.1) provides detailed revenue breakdowns by product, operating results, and cash position. While the filing also mentions the pending merger with Indivior, the primary substance of Item 2.02 is the earnings announcement and financial guidance update, which is the core material event disclosed in this section.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 72%
filed 2026-08-03
Item 7.01
The filing discloses ratification of a new collective bargaining agreement for pilots that includes accrued retention bonuses payable in Q4 2026, new pay tables, enhanced retirement plan contributions, and other employee benefits. While this is a labor agreement rather than executive compensation in the traditional sense, the disclosure centers on compensatory arrangements (bonuses, pay adjustments, retirement benefits) triggered by the agreement's ratification, which is the hallmark of exec_compensation disclosures. The material financial impact (retention bonus payout) and operational significance (preferential bidding system) make this material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
Sally Beauty Holdings issued a news release on August 3, 2026, reporting third-quarter fiscal 2026 financial results, including consolidated net sales of $935 million (up 0.2%), GAAP diluted EPS of $0.55 (up 25%), adjusted diluted EPS of $0.55 (up 8%), cash flow from operations of $81 million, and updated full-year fiscal 2026 guidance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-03
Item 5.07
This Item 5.07 disclosure reports the final voting results from the Company's Annual General Meeting of Shareholders held on July 28, 2026. The filing presents tabulated results for three matters: (1) election of 11 directors, (2) ratification of Deloitte Ltd. as independent auditors, and (3) advisory vote on named executive officer compensation. This is a classic shareholder_vote_results event, material because it documents the outcome of governance elections and auditor ratification that affect the composition and oversight of the registrant.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-03
Item 2.01
Brookfield Oaktree Holdings completed a material acquisition on July 31, 2026, acquiring all outstanding limited partnership interests and equity awards of three Oaktree partnerships (OCGH, OEP, OEP II) in exchange for cash, BAM and BN shares, ExchangeCo interests, and RSUs, representing a significant consolidation of Oaktree entities within the Brookfield structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-03
Item 5.02
Five new directors (Matt Herrington, Karly Dyck, Kunal Dusad, Brett Fox, and Aleks Novakovic) were appointed effective July 31, 2026, with Matt Herrington appointed as Chief Executive Officer and Karly Dyck as Chief Financial Officer, in connection with the consummation of the transaction and resulting in a material restructuring of the board and executive leadership.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-08-03
Item 5.03
Brookfield Oaktree Holdings amended and restated its operating agreement on July 31, 2026, revising the management and governance structure, including board composition, removal of member consent rights, and admission of ExchangeCo as a member, reflecting a material restructuring of control and decision-making authority.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-08-03
Item 8.01
Brookfield Oaktree Holdings transferred indirect ownership interests in general partner commitments of Oaktree funds from BN to Brookfield Wealth Solutions Ltd. affiliates on July 31, 2026, for fair market value consideration, representing a material change in the ownership structure of fund interests.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 99%
filed 2026-08-03
Item 1.03
Hughes Satellite Systems Corporation (HSSC), a subsidiary of EchoStar Corporation, and eleven of its wholly-owned subsidiaries filed voluntary petitions for reorganization under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of Texas on August 2–3, 2026, seeking to operate as debtors-in-possession and continue ordinary course operations.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 95%
filed 2026-08-03
Item 2.04
The Chapter 11 filing by Hughes Satellite Systems Corporation constitutes an event of default under the indentures governing HSSC's 5.25% Senior Secured Notes due 2026 and 6.625% Senior Notes due 2026, resulting in automatic acceleration of obligations under these debt instruments.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-08-03
Item 5.02
Paul Gaske resigned from all director and officer positions of EchoStar and HSSC effective immediately on July 28, 2026, in conjunction with his upcoming retirement, though he remains as a senior advisor during a transition period.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
Item 5.02
Peter Graham was appointed as a director of Invesco Mortgage Capital Inc., effective August 3, 2026, with concurrent appointments to the Audit, Compensation, and Nomination and Corporate Governance committees. Graham brings over 30 years of financial services experience, including prior CFO roles at Sallie Mae, PRA Group, and General Electric.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-03
Item 8.01
Genprex announced a strategic collaboration with Roche Diagnostics to validate biomarkers (TROP2 and PTEN) for patient selection in NSCLC clinical trials. This is a material operational and strategic partnership that advances the company's clinical development program and precision medicine approach, with anticipated completion of validation studies by end of 2026 and integration into the NSCLC clinical program thereafter. The collaboration leverages Roche's FDA Breakthrough Device Designation and represents a significant strategic alignment for accelerating patient identification and recruitment.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
TG Therapeutics issued a press release on August 3, 2026, announcing financial results for the second quarter and six months ended June 30, 2026. The disclosure includes detailed quarterly and year-to-date revenue figures ($235.8M and $437.1M in product revenue for Q2 and H1 2026), operating expenses, net income ($7.8M and $27.6M), and updated full-year 2026 revenue guidance raised to approximately $950 million. This is a standard earnings release disclosing results of operations and financial condition under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-03
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026, issued on August 3, 2026. The press release discloses comprehensive financial results including tour revenues of $199.2 million (up 19%), net loss of $1.4 million (improved $8.3 million), and Adjusted EBITDA of $32.5 million (up 31%), along with operational metrics and full-year 2026 guidance. The filing is properly furnished under Item 2.02 with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
Item 5.02
Jonathan M. Dale was appointed as President of Avidbank Holdings, Inc. and Avidbank effective August 3, 2026, reporting to Chairman and CEO Mark D. Mordell. The appointment is part of the Board's deliberate succession-planning strategy to provide leadership continuity, organizational depth, and stability.
View raw filing on EDGAR →